Personalized Disease Monitoring in Pediatric Onset Multiple Sclerosis Using the Saliva Free Light Chain Test
Esther Ganelin-Cohen1,2, Evgeny Tartakovsky3, Ely Klepfish4
1Institute of Pediatric Neurology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.
Insights
Saliva free light chains (FLC) show promise for monitoring pediatric multiple sclerosis activity. This non-invasive test correlates with MRI findings, offering a safer alternative to frequent scans.
Area of Science:
- Neurology
- Biomarker Discovery
- Immunology
Background:
- Pediatric onset multiple sclerosis (POMS) monitoring requires safe, non-invasive methods, as frequent MRI use is challenging.
- Saliva immunoglobulin free light chains (FLC) have emerged as potential biomarkers for distinguishing active from remission states in adult MS.
Purpose of the Study:
- To evaluate the effectiveness of saliva FLC measurements for monitoring disease activity in POMS patients.
Main Methods:
- Semiquantitative Western blot analysis was employed to detect and quantify FLC monomers and dimers in saliva.
- Statistical analysis included Firth logistic regression and Spearman's non-parametric correlation to assess FLC levels and their relationship with disease activity.
Main Results:
- Saliva FLC levels were significantly higher in POMS patients during relapse compared to remission.
- FLC levels demonstrated a significant correlation with the lesion load observed on MRI scans.
- Treatment, particularly corticosteroids, appeared to reduce FLC levels, and individual patient follow-ups confirmed the alignment of FLC changes with MRI data.
Conclusions:
- Non-invasive saliva FLC testing presents a viable new tool for monitoring disease activity in pediatric onset multiple sclerosis.
- This approach offers a potential alternative to reduce the need for frequent MRI examinations in POMS management.
Background:
Development of new safe methods of monitoring disease activity in the pediatric onset multiple sclerosis (POMS) is a challenging task, especially when trying to refrain from frequent MRI usage. In our recent study, the saliva immunoglobulin free light chains (FLC) were suggested as biomarkers to discriminate between remission and active MS in adults.
Objectives:
To assess utility of saliva FLC measurements for monitoring disease activity in POMS.
Methods:
We used semiquantitative Western blot analysis to detect immunoreactive FLC monomers and dimers and to calculate the intensity of their bands. Statistical tests included Firth logistic regression analysis suitable for small sample sizes, and Spearman's non-parametric correlation.
Results:
In naive POMS patients, the saliva levels of FLC in relapse were significantly higher than those in remission. Significant correlation was found between FLC levels (monomers, dimers or both) and the load of enhanced lesions in MRI scans. FLC levels may be reduced under treatment, especially as result of corticosteroids therapy. Follow-up of individual patients showed the correspondence of changes in the FLC levels to MRI findings.
Conclusions:
Our results show the potential of the non-invasive saliva FLC test, as a new tool for monitoring the disease activity in POMS.
More Related Videos
08:50Multiplexed Fluorescent Microarray for Human Salivary Protein Analysis Using Polymer Microspheres and Fiber-optic Bundles
Published on: October 10, 2013
06:50A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
Published on: May 29, 2020
